Antidiabetic Glucagon-like Peptide 1 Agonists Market

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
Antidiabetic Glucagon-like Peptide 1 Agonists Market contains market size and forecasts of Antidiabetic Glucagon-like Peptide 1 Agonists in global, including the following market information:
Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Sales, 2017-2022, 2023-2028, (Units)
Global top five Antidiabetic Glucagon-like Peptide 1 Agonists companies in 2021 (%)
The global Antidiabetic Glucagon-like Peptide 1 Agonists market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Exenatied Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Antidiabetic Glucagon-like Peptide 1 Agonists include Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi and Bristol-Myers Squibb, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Antidiabetic Glucagon-like Peptide 1 Agonists manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Antidiabetic Glucagon-like Peptide 1 Agonists Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (Units)
Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Segment Percentages, by Type, 2021 (%)
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Global Antidiabetic Glucagon-like Peptide 1 Agonists Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (Units)
Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Segment Percentages, by Application, 2021 (%)
Hospital
Pharmacy
Global Antidiabetic Glucagon-like Peptide 1 Agonists Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (Units)
Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Antidiabetic Glucagon-like Peptide 1 Agonists revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Antidiabetic Glucagon-like Peptide 1 Agonists revenues share in global market, 2021 (%)
Key companies Antidiabetic Glucagon-like Peptide 1 Agonists sales in global market, 2017-2022 (Estimated), (Units)
Key companies Antidiabetic Glucagon-like Peptide 1 Agonists sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb